FDA Approves Fast-Acting Nasal Spray as an Anti-Depression Drug


There's a new ally in the ongoing battle against depression that doctors say works faster and more efficiently than previous treatments.

Esketamine, which was recently approved by the FDA, will be sold as a nasal spray, according to the manufacturer.

The drug contains an "active portion" of ketamine, which has been long known to have antidepressant properties, though researchers don't exactly know why.

The medication will be marketed under the name Spravato and has the potential to help the more than 16 million adults in the US that suffer from depression.


Sponsored Content

Sponsored Content